Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Arcutis Biotherapeutics Q3 2026 Results: Net Income $8.8M, Up 18.8% YoY

Arcutis Biotherapeutics reported a significant turnaround for the nine months ended September 30, 2026, achieving a net income of $12.5 million compared to a net loss of $33.5 million in the prior year period. This growth was driven by a 55% increase in net product revenue to $379.2 million, though operating expenses also rose to $362.4 million due to higher selling, general, and administrative costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue143.999.2
Net income8.87.4
EPS (diluted, $ a share)$0.06$0.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+18.8%
Revenue, year on year+45.1%
Operating margin6.6%
Source

10-Q filed with the SEC, NASDAQ: ARQT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Arcutis Biotherapeutics, Inc.: key numbers

Share price
$27.33Close, Nov 17
Market cap
$3.46B
Shares outstanding
126.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Arcutis Biotherapeutics, Inc.

All →
6:39 PM ET Form 4
Insider Selling

Arcutis Biotherapeutics EVP, CLO Masaru Matsuda Sells $1.41M of Stock

Masaru Matsuda, EVP, CLO, sold 41,219 shares of Arcutis Biotherapeutics, Inc. at $31.86 to $34.32 a share (average $34.24) in 2 transactions, worth $1.41M in total between Nov 2, 2026 and Nov 4, 2026. Shares held after the trade: 111,289 (-26.4%).

Value
$1.41M
Shares
41,219
Average price
$34.24
Role
EVP, CLO
Holding change
-26.4%
Trade date
Nov 2, 2026 to Nov 4, 2026
6:39 PM ET Form 4
Insider Selling

Arcutis Biotherapeutics EVP, CMO Patrick Burnett Sells $30K of Stock

Patrick Burnett, EVP, CMO, sold 943 shares of Arcutis Biotherapeutics, Inc. at $31.86 a share, worth $30K in total on Nov 2, 2026. Shares held after the trade: 116,649 (-0.8%).

Value
$30K
Shares
943
Price
$31.86
Role
EVP, CMO
Holding change
-0.8%
Trade date
Nov 2, 2026
6:38 PM ET Form 4
Insider Selling

Arcutis Biotherapeutics Insider Todd Watanabe Sells $139K of Stock

Todd Watanabe sold 4,377 shares of Arcutis Biotherapeutics, Inc. at $31.86 a share, worth $139K in total on Nov 2, 2026. Shares held after the trade: 712,826 (-0.6%).

Value
$139K
Shares
4,377
Price
$31.86
Holding change
-0.6%
Trade date
Nov 2, 2026
4:03 PM ET 8-K
Financial Results

Arcutis Biotherapeutics Financial Results

Arcutis Biotherapeutics reported Q3 2026 net product revenues of $143.9 million, a 45% year-over-year increase driven by strong demand for its ZORYVE portfolio. The company maintained positive operating cash flow of $18.9 million and raised its full-year 2026 net product sales guidance to a range of $535 million to $545 million.

Term
quarter ended September 30, 2026

“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations.”

Frank Watanabe, president and chief executive officer
9:04 AM ET 8-K
Leadership Change

Arcutis Biotherapeutics Leadership Change

Arcutis Biotherapeutics appointed Dr. Robert Scott to its Board of Directors and the Nominating and Corporate Governance Committee, effective October 23, 2026. Dr. Scott, a former Chief Medical Officer at AbbVie and Amgen, joins as a Class II director with a term expiring in 2028. As part of his appointment, he received an initial stock option award for 20,507 shares of common stock.

4:50 PM ET Form 4
Insider Selling

Arcutis Biotherapeutics Insider Howard G. Welgus Sells $127K of Stock

Howard G. Welgus sold 4,728 shares of Arcutis Biotherapeutics, Inc. at $26.93 a share, worth $127K in total on Oct 15, 2026. Shares held after the trade: 35,207 (-11.8%).

Value
$127K
Shares
4,728
Price
$26.93
Holding change
-11.8%
Trade date
Oct 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.